Literature DB >> 19201506

High mobility group box chromosomal protein 1 acts as a proliferation signal for activated T lymphocytes.

Erik Sundberg1, Andreas E R Fasth, Karin Palmblad, Helena Erlandsson Harris, Ulf Andersson.   

Abstract

The nuclear protein high mobility group box chromosomal protein 1 (HMGB1) can be translocated extracellularly and plays a well-established role as a pro-inflammatory mediator during innate immune responses. Much less is known about the role of HMGB1 in adaptive immunity, since only a few studies have addressed the issue. We herein activated subsets of purified, primary human T lymphocytes with solid-phase bound anti-CD3 mAb and assessed the effects of recombinant HMGB1 protein on cell proliferation when added to the cultures. HMGB1 acted as a proliferative signal for human T cells during suboptimal anti-CD3 mAb stimulation. Statistically significant increased proliferation was recorded in both CD4+ and CD8+ T-cell cultures at HMGB1 concentrations ranging from 0.25 to 1.0 microg/ml. HMGB1 had no effect on proliferation in the absence of anti-CD3 stimulation or during T-cell activation obtained using high doses of anti-CD3 mAb. Our results demonstrate a direct HMGB1-mediated effect in adaptive immunity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19201506     DOI: 10.1016/j.imbio.2008.09.006

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  31 in total

1.  Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis.

Authors:  Maowei Wang; Yan Yue; Chunsheng Dong; Xiaoyun Li; Wei Xu; Sidong Xiong
Journal:  Clin Vaccine Immunol       Date:  2013-09-11

Review 2.  HMGB1 release by inflammasomes.

Authors:  Lieselotte Vande Walle; Thirumala-Dev Kanneganti; Mohamed Lamkanfi
Journal:  Virulence       Date:  2011-03-01       Impact factor: 5.882

3.  High-mobility group box 1 in multiple sclerosis.

Authors:  Zohara Sternberg; Daniel Sternberg; Trevor Chichelli; Allison Drake; Neel Patel; Chana Kolb; Kailash Chadha; Jinhee Yu; David Hojnacki
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

4.  CD8+ T-cells negatively regulate inflammation post-myocardial infarction.

Authors:  Daria V Ilatovskaya; Cooper Pitts; Joshua Clayton; Mark Domondon; Miguel Troncoso; Sarah Pippin; Kristine Y DeLeon-Pennell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-07-19       Impact factor: 4.733

Review 5.  High-mobility group box 1, oxidative stress, and disease.

Authors:  Daolin Tang; Rui Kang; Herbert J Zeh; Michael T Lotze
Journal:  Antioxid Redox Signal       Date:  2011-04-01       Impact factor: 8.401

6.  HMGB1 Promotes Hepatitis C Virus Replication by Interaction with Stem-Loop 4 in the Viral 5' Untranslated Region.

Authors:  Rong Yu; Darong Yang; Shaohua Lei; Xiaohong Wang; Xianghe Meng; Binbin Xue; Haizhen Zhu
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

7.  Are urinary levels of high mobility group box 1 markers of active nephritis in anti-neutrophil cytoplasmic antibody-associated vasculitis?

Authors:  A W S de Souza; W H Abdulahad; P Sosicka; J Bijzet; P C Limburg; C A Stegeman; M Bijl; J Westra; C G M Kallenberg
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

Review 8.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

9.  High-mobility group box 1 protein (HMGB1) neutralization ameliorates experimental autoimmune encephalomyelitis.

Authors:  Andrew P Robinson; Matthew W Caldis; Christopher T Harp; Gwendolyn E Goings; Stephen D Miller
Journal:  J Autoimmun       Date:  2013-03-17       Impact factor: 7.094

10.  Functional status of peripheral blood T-cells in ischemic stroke patients.

Authors:  Antje Vogelgesang; Verena E L May; Uwe Grunwald; Maren Bakkeboe; Soenke Langner; Henry Wallaschofski; Christof Kessler; Barbara M Bröker; Alexander Dressel
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.